- The biotech company Advanced Cell Technology (ACT) is focused on R&D of regenerative medicine and cell therapy technology to treat eye-related diseases and disorders.
- The new patent strengthens ACT’s IP position around core cell technology. It covers a novel approach to commercial-scale manufacturing of an allogenic, off-the-shelf immunotherapy platform.
- The company has a rich pipeline that includes therapies in development from the preclinical level to advanced-stage development almost ready for submission for approval.
At the moment, ACT’s preclinical program includes various cell therapies being developed to treat not only ocular disorders, but also autoimmune, inflammatory, and wound healing-related disorders.
On the other end of the spectrum, ACT’s most advanced products are in clinical trials for treatment of age-related macular degeneration, Stagardt’s macular degeneration, and myopic macular degeneration. The company is a leader in the regenerative medicine field.